However, some evidence suggests that DCIS with HER2-overexpressed and HR-negative may be associated with the highest rates of ipsilateral breast cancer recurrence, and future studies are needed to evaluate the possible prognostic and predictive role of HER2 in DCIS, also in residual disease after NAT [25]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.